Abstract
Introduction Bloodstream infections are a commonly encountered clinical syndrome of public health concern with variable epidemiology. The characteristic of resistance to multiple antibiotics by their etiologic agents has limited the options for empirical sepsis case management. This study determined the most frequent aetiologic agents responsible for bloodstream infections, their antimicrobial susceptibility patterns, and infection sources in Eastern-Central Uganda.
Materials and methods This retrospective study involved analysis of all non-duplicate blood culture reports from 2019 to 2021. The frequency and percentage of significant pathogenic organisms and contaminants were calculated. Positivity distribution including infection sources was determined. World Health Organization Network (WHONET) 2022 desktop software was used for antimicrobial susceptibility data analysis.
Results The 1364 participants had a diagnostic yield of 114(6.8%) and a 1.5% contamination rate. Over 37% and 13% of infections were hospital and community-acquired respectively. Most etiologic agents were Gram-positive bacteria dominated by Staphylococcus aureus 39(34.2%). Gram-negatives mainly included unspecified Coliforms 12(10.5%), and E. coli 10(8.8%). Polymicrobial growth existed in 4(0.3%) cases. S. aureus was mainly resistant to Penicillin G (100%), Cefoxitin (60%), and Erythromycin (52.2%). Both Escherichia coli and unspecified coliforms showed high resistance to Ampicillin (87.5%) and third-generation Cephalosporins (100%). The least resistance was to Chloramphenicol and Carbapenems.
Conclusion BSIs are mainly due to Gram-positive bacteria. Suspected sepsis cases by S. aureus in this region can be empirically managed using Gentamicin. Microbiology services should be routinely utilized to guide antimicrobial use, monitor blood culture contamination rates and resistance trends to strengthen regional antimicrobial stewardship.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Jinja Hospital Research and Ethics Committee approved the study with registration number JREC 159/2022. The data was obtained from records of personnel who seek medical services at the facility. This is kept in medical records including patients files, laboratory request forms and information systems for proper care and later reference. The Microbiology Laboratory records were anonymously analyzed for this study and no consent was obtained from individual personnel.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The dataset to support the conclusions is published and freely accessible via the Dryad website (https://doi.org/10.5061/dryad.3bk3j9kqg)
